



CLAIMS

1. Use of ~~a therapeutically effective amount of~~ Compound 1:



or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof in the manufacture of a medicament for the treatment of pain caused by inflammation or ~~an~~ the initiation of the inflammatory response in a subject in need thereof, wherein the medicament is to be administered to the subject, wherein the pain caused by inflammation or the initiation of the inflammatory response is associated with hyperalgesia, arthritis pain, low back pain, neuropathic pain, ~~visceral pain,~~ pain due to cancer, pain due to injury, pain due to cutaneous₂/subcutaneous₂ or joint inflammation, pain due to back disorders, or neck pain.

2. Use of Compound 1:



or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof in the manufacture of a medicament for the prevention of pain caused by inflammation or the initiation of the inflammatory response, wherein the pain caused by inflammation or the initiation of the inflammatory response is associated with hyperalgesia, arthritis pain, low back pain, neuropathic pain, pain due to cancer, pain due to injury, pain due to cutaneous₂/subcutaneous₂ or joint inflammation, pain due to back disorders, or neck pain.

- ~~23~~. The use of claim 1 or 2, wherein the pain is caused by initiation of the inflammatory response.
- ~~34~~. The use of any one of the foregoing claims, wherein the pain is associated with hyperalgesia.
5. The use of any one of claims 1-3, wherein the pain is associated with arthritis pain, low back pain, pain due to back disorders, or neck pain.
6. The use of any one of claims 1-3, wherein the pain is associated with neuropathic pain.
- ~~47~~. The use of any one of ~~claims 1-3~~the foregoing claims, wherein the pain is chronic pain or subacute pain.
- ~~58~~. The use of ~~any of the foregoing claims~~claim 7, wherein the chronic pain is arthritis pain, low back pain, neuropathic pain, ~~visceral pain~~, pain due to cancer, pain due to injury, pain due to joint inflammation, pain due to back disorders, or neck pain.
- ~~69~~. The use of claim ~~58~~, wherein the pain due to cancer is caused by cancer involving intraperitoneal abdominal and pelvic organs or bone cancer or bone metastases.
- ~~710~~. The use of claim ~~58~~, wherein the pain due to injury is caused by bone, ligament, or tendon injury.
- ~~811~~. The use of any one of the foregoing claims, wherein administration of the medicament~~Compound 1~~ reduces pain to a similar degree as administration of a central-nervous system-acting opioid.
- ~~912~~. The use of claim ~~811~~, wherein the central-nervous system-acting opioid activates a *mu* receptor.
- ~~1013~~. The use of claim ~~811~~, wherein the central-nervous system-acting opioid is morphine.
- ~~1114~~. The use of any one of the foregoing claims, wherein administration of the medicament does not result in any central-nervous system side effects.
- ~~1215~~. The use of claim ~~1114~~, wherein the central nervous system side-effects are addiction, constipation, sedation, impaired mentation, somnolence, respiratory depression, nausea, dysphoria, or seizures.
- ~~1316~~. The use of claim ~~1215~~, wherein administration of the medicament does not result in constipation.
- ~~1417~~. The use of claim ~~1215~~, wherein administration of the medicament does not result in addiction.

~~1518.~~ The use of any one of the foregoing claims, wherein ~~Compound 1~~ administration of the medicament results in synergistic activation of *kappa* and *delta* opioid receptors.


~~1619.~~ The use of claim ~~1518~~, wherein the synergistic activation~~synergy~~ results from allosteric modulation of *kappa* receptors by *delta* receptor activity.

~~1720.~~ The use of any one of the foregoing claims, wherein ~~administration of Compound 1~~ the efficacy of the medicament for treatment of acute pain is similar or superior to the efficacy of a *kappa* receptor agonist for treatment of acute pain.

~~1821.~~ The use of any one of the foregoing claims, wherein ~~administration of Compound 1~~ the efficacy of the medicament for treatment of hyperalgesia is similar or superior to the efficacy of a *kappa* receptor agonist for treatment of hyperalgesia.


~~1922.~~ The use of any one of the foregoing claims, wherein administration of ~~Compound 1~~ the medicament results in reduced urinary output compared to administration of a *kappa* receptor agonist.

20. — Use of the Compound 1:



~~or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof in the manufacture of a medicament for the treatment of pain caused by the initiation of the inflammatory response.~~

21. — Use of the Compound 1:



or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof in the manufacture of a medicament for the prevention of pain caused by inflammation or the initiation of the inflammatory response, wherein the pain caused by inflammation or the initiation of the inflammatory response is associated with hyperalgesia, arthritis pain, low back pain, neuropathic pain, visceral pain, pain due to cancer, pain due to injury, pain due to cutaneous/subcutaneous or joint inflammation, pain due to back disorders, or neck pain.